Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising an H1 antihistamine and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.

Abstract: There is provided a gelator that is capable of forming a gel by an extremely small amount of addition in a wide pH range from acidic to alkaline regions, and a gel having high environmental compatibility, biocompatibility, and biodegradability. A gelator comprising: a lipid peptide of Formula (1) wherein R1 is a C9-23 aliphatic group, R2 is a hydrogen atom or a C1-4 alkyl group optionally having a C1-2 branched chain, R3 is a —(CH2)n—X group, n is a number from 1 to 4, and X is an amino group, a guanidino group, a —CONH2 group, or a 5-membered ring optionally having 1 to 3 nitrogen atoms, a 6-membered ring optionally having 1 to 3 nitrogen atoms, or a fused heterocycle including a 5-membered ring and a 6-membered ring that optionally has 1 to 3 nitrogen atoms); or a pharmaceutically usable salt of the lipid peptide.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: To provide a thickening composition which exhibits excellent feelings in use, namely, exhibits excellent freshness, non-stickiness and blend into skin feeling, and does not leave any residue on skin, which can stably keep the viscosity thereof in a low to moderate-level viscosity range and which, even when a salt-type ingredient is incorporated therein, does not undergo viscosity change, and also a cosmetic preparation containing the composition. A thickening composition which comprises (a) from 0.1 to 2% by mass of a specific hydrophobic denatured polyether urethane (associative thickener) and (b) from 0.1 to 2% by mass of a microgel to be obtained by grinding a gel of a hydrophilic compound having a gelling capability, in a ratio of component (a)/component (b) of from 0.1/0.9 to 0.9 to 0.1 (by mass), and which has a viscosity of from 50 to 50,000 mPa·s (with BL-type viscometer, 12 rotations, 25° C.); and a cosmetic preparation containing the thickening composition.

Abstract: A continuous process for the preparation of gelatin based nanoparticles in a reactor having a process channel having a mixing element therein, the process having the following steps: A) feeding separately an aqueous gelatin solution at a first rate and a water-miscible organic solvent at a second rate to the process channel of the reactor to be mixed therein, to form a suspension of non-crosslinked gelatin based nanoparticles and B) crosslinking the non-crosslinked gelatin based nanoparticles, wherein the sum of the first rate and the second rate is chosen such that the reactor has a mixing efficiency as determined by the Villermaux/Dushman method of between 0.1 and 1.5 and the period from the time point at which the aqueous gelatin solution is fed to the reactor to the time point at which the mixture of the aqueous gelatin solution and the organic solvent contacts the mixing element is at most 15 seconds.

Abstract: The disclosure provides for saccharide-peptide based hydrogels, the functionalization of the saccharide-peptide based hydrogels with one or more biological agents, and the encapsulation of one or more biological materials and/or pharmaceutical agents in the hydrogels. The disclosure further provides for the use of the saccharide-peptide based hydrogels in treating a disease or disorder in a subject.

Abstract: The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

Abstract: Conjugated molecules are prepared that comprise a predetermined number of oligo conjugation components. The conjugated molecules also may comprise one or more detectable labels. Preparation of these molecules can be implemented according to an asymmetric or a symmetric conjugation strategy.

Abstract: The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.

Abstract: A protein nanocapsule having a single-protein core and a thin polymer shell anchored covalently to the protein core.

Abstract: The present invention provides compositions and methods for the delivery of nucleic acids to a cell. The present invention additionally provides compositions and methods for the treatment of a disease or disorder, particularly cancer. In a particular embodiment, the composition comprises at least one pharmaceutically acceptable carrier and at least one liposome or dendrimer comprising at least two chemotherapeutic agents with different mechanisms of action and at least two inhibitors of cellular drug resistance.

Abstract: Microparticles and nanoparticles and compositions thereof are provided. The microparticles and nanoparticles and compositions may be used for the treatment of musculoskeletal disease, such as osteoarthritis and injury.

Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.

Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.

Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.

Abstract: Described herein are biodegradable drug delivery conjugates for effectively delivering bioactive agents to a subject. The drug delivery conjugates comprise a water-soluble high molecular weight linear biodegradable polymer backbone comprising a plurality of linear water-soluble polymeric segments connected to one another by a first (main-chain) cleavable linker, wherein a bioactive agent is covalently bonded to at least one water-soluble polymeric segment, at least one cleavable linker, or a combination thereof. The conjugates possess numerous advantages over prior art delivery conjugates. Also described herein are methods for making and using the conjugates.

Abstract: The present disclosure relates to compositions and methods for the treatment of a disease, e.g., cancer or pathogenic infection, using a bioconjugated nanoparticle comprising a biocompatible quantum dot conjugated to a targeting moiety. The targeting moiety allows for the nanopaticle to bind to a cancer cell or pathogenic organism. The quantum dot, upon excitation by soft x-rays, emits electromagnetic radiation at a frequency of ultraviolet light, thereby allowing for the disruption of the DNA found in the cancer cell or pathogenic organism.

Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

Abstract: Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as by non-covalent bonds. The complexes and compositions can be used for administration to subjects, such as for treating a subject with a musculoskeletal disease such as osteoarthritis and/or degenerative joint disease. The complexes and compositions can be used in different mammals, including dogs, horses, and humans.

Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.

Abstract: Multivalent fluorescent probes and methods of using these multivalent fluorescent probes for in vitro and in vivo imaging are described.

Abstract: The present disclosure provides compositions and methods based on peptide-detectable agent conjugates that are useful for imaging beta cell mass.

Abstract: The present invention relates to a formulation of indocyanine green in the form of a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises indocyanine green, at least one amphiphilic lipid and at least one solubilizing lipid. It relates also to a process for the preparation and to the use of the formulation.

Abstract: A method of preparing a hydrogen-containing 13C compound test sample exhibiting an enhanced 13C nuclear magnetic resonance (NMR) signal when exposed to a 13C NMR pulse sequence is disclosed. In the disclosed method, the hydrogen-containing 13C compound is mixed with hyperpolarized 129Xe in the gaseous state, and the mixture is subsequently frozen within a magnetic field. The magnetic field strength is then reduced sufficiently so that spin polarization is transferred from the hyperpolarized 129Xe to the compound. The magnetic field strength is then increased, and the mixture is thawed to obtain the test sample.

Abstract: The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs.

Abstract: A system for removing microorganisms from a surface is described. The system includes a conducting member, a voltage source, and an electrostatic field controller. The conducing member includes a nonwoven material incorporating conductive fibers. The controller is electrically connected to the conducting member and is configured to apply a DC voltage of about 15 volts or less to the conducting member via the voltage source. The surface to be contacted can include any surface present in households, food industry facilities, medical facilities, etc. Such surfaces can include tables, countertops, walls, cabinets, doors, door handles, door knobs, etc. The system can also be used to treat devices used in the aforementioned environments, such as food preparation equipment, medical devices, household appliances, etc. The system can reduce the amount of microorganisms on the surface by at least about 1 log (90%) without the use of chemicals, high voltages, or long exposure times.

Abstract: Provided is an apparatus for sterilizing containers with a conveying device, which conveys the containers along a pre-set conveying path. A first sterilization device acts upon at least one area of the containers with radiation in order to sterilize them. A checking device is arranged downstream with respect to the first sterilization device along the conveying path in order to check the sterilization procedure. The checking device is used for analyzing at least one medium occurring in the region of the containers.

Abstract: A system for sterilizing a fluid includes a fluid source and a sterilization container bounding a fluid flow path that is in fluid communication with the fluid source. The sterilization container is comprised of one or more polymeric walls. An electron beam generator is configured to direct an electron beam through at least a portion of the fluid flow path of the sterilization container, the electron beam being sufficient to sterilize a fluid within the fluid flow path.

Abstract: Disclosed is a UV sterilizer. The UV sterilizer includes a body including a top surface and a sidewall, at least one first UV LED chip disposed on the top surface of the body, and at least one second UV LED chip disposed on the sidewalls of the body. The body is freely movable among various target spaces to be sterilized, whereby the UV sterilizer can perform sterilization in a variety of spaces without being limited to a specific space.

Abstract: The present invention relates to a device for reducing the total number of pathogens of one or more pathogen living in turf. This invention provides a number of devices to safely deliver the UV light to plants. In one embodiment, the device is made of a plurality of UV emitting devices imbedded in a face of a stationary bed knife blade. The plurality of UV emitting devices forming an arc of substantially continuous UV coverage. This modified bed-knife can be incorporated into a lawn mower to provide UV radiation, while at the same time cutting the turf.

Abstract: A time release biocide dispensing device for controllably dispensing biocide into a condensation line of an air conditioner at predetermined concentrations and volumes over a duration. The device utilizes principles of pressure equilibrium and material resistance to dispense a regulated and steady flow of the biocide into the line. The device utilizes a controller, a pump, a container, a fluid tube, and a coupling member. The device is configured to easily attach to the line and facilitate setting of the controller, such that minimal tools and expertise are needed for operation. A container attaches to the line and holds a biocide and a volume having a vacuum. A pump forces a fluid into the vacuum to disturb the equilibrium, and thus partially force the biocide into the line. A resistance member restricts the flow to drops to further regulate the flow of the biocide into the line.

Abstract: [Problem to be Solved] A device and a method for efficiently decontaminating a device used to culture cells are provided. [Means for Solving Problem] A decontamination device for decontaminating a device used to culture cells, manipulate microorganisms, or perform a sterility test, the device comprising an ultrasonic atomizer that atomizes a peracetic acid disinfectant by using ultrasonic oscillation to discharge droplets, a diffusion fan, a temperature-humidity sensor, and a controller.

Abstract: An ultraviolet radiation system to decontaminate small objects such as TV remote controls, hospital bed controls, cell phones, computer tablets and the like which are present in a hospital or other health care facility. The system includes a plurality of UVC lamps arranged in a table top sized housing and having a UVC transmissive shelf in the housing for support of objects to be decontaminated. The system has a microprocessor based controller and can kill Clostridium difficile and other pathogens to thereby decontaminate items in 30 seconds or less.

Abstract: An indicator composition can be exposed to various environmental conditions stimuli such as in sterilization or storage processes. This indicator composition has a) a first polymeric particle comprising a solid continuous polymeric phase and a first reactant, the first polymeric particle having a mode particle size equal to or less than 50 ?m; and b) a second reactant outside of the first polymeric particle, which second reactant is capable of reacting with the first reactant when exposed to a chosen environmental condition stimulus. The indicator composition can be used by exposing it to the environmental condition stimulus for a sufficient time to cause a detectable change in the indicator composition such as a detectable color change.

Abstract: Animal scent lure systems and devices are provided in which scent element holder devices are employed to removably secure a scent element to an animal decoy, for example, to attract wild animals such as deer. For example, an animal lure device includes a scent element holder device for removably holding an animal scent element. The scent element holder device includes a first connecting element to connect the scent element holder device to a stationary object, a second connecting element for removably securing a scent element to the scent element holder device; and an extension arm element connecting the first and second connecting elements. The extension arm element is adapted to maintain the second connecting element offset from the stationary object (e.g., animal decoy) to which the first connecting element is attached.

Abstract: A scent producing apparatus, the apparatus constituted of: a single atomizer; a control circuitry; and a plurality of scent reservoirs each with a respective controllable release mechanism arranged to release a controlled quantity of the contents of the scent reservoir to the atomizer responsive to the control circuitry. Optionally, at least one solvent reservoir with a respective controllable release mechanism is further provided and arranged to release a controlled quantity of the contents of the at least one solvent reservoir to the single atomizer responsive to the control circuitry. Optionally, a neutralizing agent is provided thus enabling scent production with a pre-determined persistence.

Abstract: High refractive index acrylic device materials with reduced glistenings are disclosed. The device materials are particularly suitable for use as ophthalmic or otorhhinolaryngological device materials and comprises a poly(phenyl ether)-containing monomer and/or a poly(phenyl ether)-containing cross-linking agent.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Abstract: Materials and methods for improving the biological properties and electromechanical performance of collagen scaffolds used for cell transplantation, including the fixation of biocompatible reagents and adhesion molecules which control cell adhesion, apoptosis, survival and/or differentiation simultaneously. The grafting of adhesion molecules to collagen matrices renders same suitable for use in vascular and cardiothoracic surgery/medicine, as well as in cell therapy for the heart and in artificial heart muscle engineering. Also, a simple method for grafting and optimising the presentation of adhesion peptides or biological agents when the scaffold is made from collagen and/or contains accessible thiol, amine or carboxyl groups.

Abstract: A composite material including biocompatible and bioresorbable glass, a biocompatible and bioresorbable matrix polymer and a coupling agent capable of forming covalent bonds. The composite also includes a compatibilizer, where at least 10% of the structural units of the compatibilizer are identical to the structural units of the matrix polymer, and the molecular weight of the compatibilizer is less than 30000 g/mol. The use of this composite, a medical device which includes the composite and a method for preparing the composite are also disclosed.

Abstract: It is a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.

Abstract: A method for forming a material in an in situ medical device by initiating polymerization of water soluble polymer precursors in an aqueous solution during or after transport of the polymerizable solution from its storage container to a space inside the in situ medical device is described. The stored aqueous solution with water soluble precursors lacks a free radical initiator which, in a powder form, is introduced into the aqueous solution during or after its transport into the space inside the in situ medical device. This storage and delivery system provides greater stability to the stored aqueous solution, allowing it to be stored at ambient temperature and providing extended shelf life over the solutions used in existing in situ polymerization systems. The flexibility to store and deliver/transport only one aqueous solution, instead of requiring the use of two different solutions, is also a benefit.

Abstract: The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.

Abstract: A method of forming and the resulting membrane composition for securement to a patient's bone or tissue to reduce the formation of tissue adhesions following a surgical procedure comprises a first component and a second component. The first component comprises a hydrogel including at least one crosslinked polymer. The second component comprises a textile component. The composition has a thickness between about two tenths of a millimeter (0.2 mm) to about six tenths of a millimeter (0.6 mm), a suture retention strength between about one Newton (1 N) to about thirteen Newtons (13 N), a static coefficient of friction between about one hundredth (0.01) and about one-half (0.5), a kinetic coefficient of friction between about one hundredth (0.01) and about one-half (0.5) and a flexibility of less than thirty millimeters (30 mm) bend length. A method of reducing the occurrence of tissue adhesions following surgery comprises applying the membrane composition to a surgical site.

Abstract: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.

Abstract: A modified medical device substrate surface designed to improve adhesion of biomimetic surfactants to the medical device surface, thus reducing the risk of thrombosis is described. The surface modification is accomplished through either an application of a tie layer of a hydrophobic material on the substrate surface intermediate the biomimetic coating or through incorporation of a hydrophobic dopant in the polymeric substrate prior to extrusion or molding. Either method creates a hydrophobically modified surface that enhances the biomimetic surfactant bonding strength.

Abstract: A surgical fluid manager includes a pump releasably engageable to tubing and a user interface. The user interface is configured to enable finger-touch selection of a fluid flow rate through the tubing and configured to operate in at least one of a first mode or a second mode. In the first mode, the flow rate is controlled via direct selection of one of a plurality of selectable digital numeric values, while in the second mode the flow rate is controlled via user selection of one alphanumeric identifier within a scale of alphanumeric identifiers. Each respective alphanumeric identifier directly corresponds to just one instrument size within a scale of instrument sizes.

Abstract: An apparatus for cleansing and promoting tissue growth in wounds, in which irrigant fluid optionally containing cell nutrients and/or other physiologically active material from a reservoir connected to a conformable wound dressing and wound exudate from the dressing are recirculated by a device for moving fluid through a flow path which passes through the dressing, a biodegradable scaffold in contact with the wound bed and a means for fluid cleansing and back to the dressing. The apparatus has means for supplying thermal energy to the fluid in the wound. The cleansing means (which may be a single-phase, e.g. micro-filtration, system or a two-phase, e.g. dialytic system) removes materials deleterious to wound healing, and the cleansed fluid, still containing materials that are beneficial in promoting wound healing, is returned to the wound bed. The dressing and a method of treatment using the apparatus.

Abstract: An equipment housing, in particular the housing of a blood treatment device, having a housing wall and a closing flap for closing an opening in the housing wall. The closing flap is rotatably mounted with respect to a coupling element via a second pivot whereby the coupling element is rotatably mounted with respect to the housing wall via a first pivot. With the two pivots, the closing flap 20 can be disposed in at least a second and a third opened working position, in both of which positions the opening in the housing wall is not closed.

Abstract: A device is arranged to detect a configuration of withdrawal and return devices (1, 14, 111, 112, 211, 212, 702, 703, 802, 803) coupling an extracorporeal blood flow circuit (20) to a cardiovascular system of a subject. The device comprises a signal processor (29), which is configured to receive a primary measurement signal obtained by a primary pressure sensor (4a, 4b, 4c) in the extracorporeal blood flow circuit (20). The device is further configured to process the primary measurement signal for extraction of primary pressure data originating from a subject pulse generator (3?) in the cardiovascular system or extracorporeal blood flow circuit (20), the primary pressure data comprising at least a part of a first pulse from the subject pulse generator (3?). The device is also configured to calculate a parameter value from the primary pressure data and to determine the configuration based at least partly on the parameter value.